Examining New Treatment Options for Triple Negative Breast Cancer After Surgery

Recruiting · Phase 3 · Triple Negative Breast Cancer · 41 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well the medicine sacituzumab govitecan-hziy (SG) combined with pembrolizumab works for patients with triple negative breast cancer. These are patients who still have cancer after surgery and treatment before surgery. Researchers want to see if this combination is better than the treatment chosen by their doctor, which may include pembrolizumab alone or with capecitabine.

The trial's ID number is NCT05633654. This is a Phase 3 trial, which means it is looking at the effectiveness and safety of the treatments. It is regulated by the FDA, and the study hopes to include about 1,514 participants.

Who can join

Participants must be 18 years or older. They should have triple negative breast cancer that remains after treatment. They must also be recovering well from surgery and have good overall health. Some people, like those with advanced cancer or certain heart conditions, cannot join. The trial team will confirm who is eligible.

Condition

Triple Negative Breast Cancer

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in this study will be placed into one of two groups by chance. One group will receive sacituzumab govitecan-hziy and pembrolizumab for up to 8 cycles. The other group will receive a treatment chosen by their doctor, which could be pembrolizumab alone or with capecitabine. Treatments will continue unless there is a return of cancer or other reasons to stop.